Indian pharma firms see fall in rate of final product approvals from USFDA

Analysts are optimistic that the sanction rate is likely to witness a pickup in the second half of the year.

Indian pharmaceutical firms are seeing a slight dip in the rate of final product approvals from the US drug regulator in the first half of 2018 calendar year. Around 101 final approvals were received till date this year, down from 126 during the same period last year. 

Indian pharma companies, however, had a great 2017 in terms of approvals from the US Food and Drug Administration (USFDA). They received final approvals for 304 abbreviated new drug applications (ANDAs) out of the total 846 given globally — accounting for almost 36 per cent of the overall approvals.

Though the